Pareto Securities AS initiates equity research coverage of ExpreS2ion with a Buy rating and target price of 60 SEK per share
24 juni, 2021
The major contributors of value in the sum-of-the-parts valuation are ExpreS2ion’s 34% stake in its joint venture with NextGen Vaccines, AdaptVac, ExpreS2ion’s breast cancer vaccine candidate, ES2B-C001 HER2-cVLP, the company’s Influenza program as part of the INDIGO consortium, and royalties from the PREVENT-nCoV COVID-19 vaccine program.
The full English version of the company-sponsored equity research report is attached to this press release.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se
Ämnen i artikeln
Pareto Securities AS initiates equity research coverage of ExpreS2ion with a Buy rating and target price of 60 SEK per share
24 juni, 2021
The major contributors of value in the sum-of-the-parts valuation are ExpreS2ion’s 34% stake in its joint venture with NextGen Vaccines, AdaptVac, ExpreS2ion’s breast cancer vaccine candidate, ES2B-C001 HER2-cVLP, the company’s Influenza program as part of the INDIGO consortium, and royalties from the PREVENT-nCoV COVID-19 vaccine program.
The full English version of the company-sponsored equity research report is attached to this press release.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se
Ämnen i artikeln
Aktier
Aktieanalyser
Aktier
Aktieanalyser
Marknadsöversikt
1 DAG %
Senast
1 mån
